首页> 外文OA文献 >The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: Leukocyte- and context-specific effects.
【2h】

The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: Leukocyte- and context-specific effects.

机译:喹啉-3-甲酰胺帕奎莫德(aBR-215757)在无菌炎症期间减少白细胞募集:白细胞和环境特异性作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Quinoline-3-carboxamides (Q-compounds) are currently in clinical development for both autoimmune disease and cancer. We have previously shown that the Q-compound paquinimod (ABR-215757) significantly ameliorates disease symptoms in several mouse models of human inflammatory disease. Considering that recruitment of inflammatory cells into tissue is a common denominator of these models, we have in this report investigated whether paquinimod would interfere with cell accumulation during sterile peritoneal inflammation. To mimic the cell recruitment elicited by tissue injury, we used necrotic cells to induce the acute inflammatory response. We show that per oral treatment with paquinimod significantly reduced the accumulation of Ly6C(hi) inflammatory monocytes and eosinophils, but not neutrophils, in this model, and that this correlated with reduced number of such cells also in the omentum. Treatment also reduced the accumulation of these cell populations at a subcutaneous site of inflammation. In alum-induced inflammation, however, neutrophils were the dominant cell population and paquinimod failed to reduce the accumulation of inflammatory cells. Taken together, our results indicate that paquinimod selectively inhibits cell recruitment during acute sterile inflammation, but that this effect is context-dependent. These data have important implications for the understanding of the mechanism of action of Q-compounds in both pre-clinical and clinical settings.
机译:喹啉-3-羧酰胺(Q-化合物)目前正在针对自身免疫性疾病和癌症进行临床开发。先前我们已经表明,Q化合物paquinimod(ABR-215757)在人类炎症性疾病的几种小鼠模型中可显着改善疾病症状。考虑到炎症细胞在组织中的募集是这些模型的共同点,我们在本报告中研究了帕喹莫德在无菌性腹膜炎症过程中是否会干扰细胞蓄积。为了模拟由组织损伤引起的细胞募集,我们使用坏死细胞诱导急性炎症反应。我们显示,在该模型中,用帕奎尼莫德进行口服治疗可显着降低Ly6C(hi)炎性单核细胞和嗜酸性粒细胞的积累,但不会减少嗜中性粒细胞的积累,并且这与网膜中此类细胞的数量减少有关。治疗还减少了这些细胞群体在炎症皮下部位的积累。然而,在明矾引起的炎症中,嗜中性粒细胞是占主导地位的细胞群,而帕喹莫德未能减少炎症细胞的积累。两者合计,我们的结果表明,帕奎尼莫德在急性无菌炎症过程中选择性抑制细胞募集,但这种作用是上下文相关的。这些数据对于了解Q化合物在临床前和临床环境中的作用机理具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号